Referenser och regelverk

  1. Fass. Skyddsinformation: fakta för förskrivare. Läkemedelsindustriföreningen (LIF);
  2. Arbetsmiljöverket.
  3. Hedmer M, Jönsson BAG and Nygren O. Development and validation of methods for environmental monitoring of cyclophosphamide in workplaces. Journal of Environmental Monitoring. 2004;6:979.
  4. Hedmer M, Wohlfasrt G. Hygienic guidance values for wipe sampling of antineoplastic drugs in Swedish hospitals. J Environ Monit. 2012;47(7):1968-1975.
  5. Hedmer et al. Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. The Annals of Occupational Hygiene. 2005;49(7):629-37.
  6. Wengström Y, Foubert J, Margulies A, Roe H, Bugeia S. Extravasering: Riktlinjer 2007. Extravasation Guidelines 2007.. London: European Oncology Nursing Society (EONS); 2007.
  7. Connor TH, Shults M, Fraser MP. Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23 and 37 degrees C using a desiccator technique. Mutat Res. 2000 Oct;10;470(1):85-92.
  8. Opiolka S, Molter W, Goldschmidt R, Erich E, Schoppe G. Umgang mit zytostatika: Besteht aus ausreichender Personenschutz bei der Zytostaika_Zuberitung?. Krankenhaus Technik. 1998;56-8.
  9. Nationellt nätverk i säker cytostatikahantering. Rekommendationer om städning i samband med cytostatikabehandling. Lund: Regionalt cancercentrum Väst; 2018.
Till toppen av sidan